文献速递流行病学与生物统计基础与转化研究

产前暴露于哮喘药物与神经发育障碍及教育困难风险:系统综述与荟萃分析

Prenatal exposure to asthma medications and risk of neurodevelopmental disorders and educational difficulties: A systematic review and meta-analysis.
PubMed 文献 · PLoS Med · 2026-06-01

该系统综述纳入8项研究(n=3,867,170),评估产前哮喘药物暴露与神经发育及教育结局的关联。三项研究的荟萃分析显示,β2受体激动剂暴露与孤独症谱系障碍(ASD)显著相关(孕前aOR 1.34,孕期aOR 1.29)。与注意缺陷多动障碍(ADHD)的关联仅见单篇报道,需进一步验证。

要点

  • 产前β2受体激动剂暴露与ASD风险增加相关,孕前和孕期aOR分别为1.34和1.29。
  • 与ADHD的关联仅来自一项研究,证据尚不充分。
  • 现有研究存在残余混杂和暴露错分,且难以区分药物效应与母体哮喘本身影响。

核心结论

  • 荟萃分析提示产前β2受体激动剂暴露与ASD存在关联。
  • 与ADHD的关联仅见单篇报道,需进一步证实。
  • 基于当前检索策略,未见与沟通技能、运动技能、问题解决和个人社交技能或脑瘫的关联报道。

研究设计与样本

  • 系统综述遵循PRISMA指南和PECO框架,检索PubMed、Medline和Embase数据库。
  • 最终纳入8项研究,共3,867,170名参与者,包括5项队列研究和3项病例对照研究。
  • 采用Newcastle-Ottawa量表评估研究质量,使用随机效应模型进行荟萃分析。
  • 异质性评估采用Cochran Q检验和I2检验。

主要发现

  • 三项研究的荟萃分析(n=1,380,871)显示,β2受体激动剂暴露与ASD显著相关:孕前aOR 1.34(95% CI [1.19,1.52]),孕期aOR 1.29(95% CI [1.16,1.42])。
  • 异质性较低,未发现显著发表偏倚。
  • 纳入研究结果不一致,部分研究报告与ASD或ADHD的关联,但未一致复制。

关键数值与推荐

  • 纳入标准为研究产前暴露于一种或多种哮喘药物与神经发育或教育结局的关联。
  • 排除将哮喘药物用于其他适应症的研究。
  • 荟萃分析仅针对β2受体激动剂暴露与ASD的关联,涉及三项研究。

临床怎么用

  • 临床应继续强调孕期哮喘控制的重要性,但需告知患者β2受体激动剂暴露与ASD的潜在关联。
  • 该关联不应改变当前孕期哮喘用药指南,需权衡母胎风险与神经发育风险。
  • 对β2受体激动剂暴露的儿童可关注神经发育监测,但无需过度干预。

局限性

  • 纳入研究存在残余混杂和暴露错分。
  • 荟萃分析纳入研究数量少,未能充分区分药物效应与母体哮喘本身的影响。
  • 与ADHD的关联仅基于单项研究,证据强度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since asthma exacerbations during pregnancy risk maternal and fetal health, continued medication is important. However, some studies have reported adverse neurodevelopmental outcomes following prenatal exposure to asthma medication. Therefore, this systematic review aimed to collate the existing evidence on the associations between prenatal exposure to asthma medication and neurodevelopmental and educational outcomes. METHODS AND FINDINGS: A systematic review was conducted in accordance with PRISMA guidelines and the PECO framework. PubMed, Medline and Embase databases were searched for studies investigating prenatal exposure to one or more asthma medication and neurodevelopmental or educational outcomes published, in English, between January 2003 and September 2024, and updated in November 2025. Studies of asthma medication used for other indications were excluded. Study quality was assessed using the Newcastle-Ottawa scale. Random-effects meta-analyses were conducted where appropriate and heterogeneity was evaluated using Cochran's Q and I2 tests. Of 16,824 studies identified by the initial search, seven were eligible for inclusion. All investigated beta-2-adrenergic agonists (B2AA), with one including B2AA as mono- and polytherapy-and one study also investigated inhaled corticosteroids (ICS) exposure. Two reported associations with autism spectrum disorder (ASD) and one with attention-deficit hyperactivity disorder (ADHD). An updated search identified one additional eligible study, which examined both ADHD and ASD, as well as other neurodevelopmental disorders. The included eight studies (n = 3,867,170 participants) comprised cohort (n = 5) and case-control (n = 3) designs and reported inconsistent results. Meta-analysis of three studies (n = 1,380,871) indicated significant associations with ASD for exposure to B2AA both preconception (aOR 1.34, 95% CI [1.19,1.52]) and during pregnancy (aOR 1.29, 95% CI [1.16,1.42]). Heterogeneity was low, with no evidence of significant publication bias. Limitations of the included studies comprised residual confounding and exposure misclassification. Additionally, studies included in the meta-analysis were few in number and did not adequately distinguish between medication effects and underlying maternal asthma. CONCLUSION: Meta-analysis suggested an association between prenatal exposure to B2AA and ASD. An association with ADHD, reported in a single study, requires corroboration. To date, based on our search strategy, no association has been reported with communication skills, motor skills, problem-solving and personal-social skills, or cerebral palsy.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Shakhshir LA, Karain A, Pell JP, et al. Prenatal exposure to asthma medications and risk of neurodevelopmental disorders and educational difficulties: A systematic review and meta-analysis. PLoS Med. 2026. PMID: 42224295. doi:10.1371/journal.pmed.1005100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。